|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIF5B |
Gene summary for KIF5B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIF5B | Gene ID | 3799 |
| Gene name | kinesin family member 5B | |
| Gene Alias | HEL-S-61 | |
| Cytomap | 10p11.22 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P33176 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3799 | KIF5B | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.89e-06 | -4.09e-01 | 0.0155 |
| 3799 | KIF5B | HTA11_78_2000001011 | Human | Colorectum | AD | 1.16e-02 | 4.72e-01 | -0.1088 |
| 3799 | KIF5B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.82e-11 | 8.28e-01 | 0.294 |
| 3799 | KIF5B | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.51e-05 | 5.90e-01 | 0.281 |
| 3799 | KIF5B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.16e-17 | 1.24e+00 | 0.3859 |
| 3799 | KIF5B | A001-C-207 | Human | Colorectum | FAP | 1.46e-03 | 2.02e-01 | 0.1278 |
| 3799 | KIF5B | A015-C-203 | Human | Colorectum | FAP | 7.42e-28 | -2.57e-01 | -0.1294 |
| 3799 | KIF5B | A015-C-204 | Human | Colorectum | FAP | 1.98e-04 | -7.31e-02 | -0.0228 |
| 3799 | KIF5B | A014-C-040 | Human | Colorectum | FAP | 4.39e-03 | -1.38e-01 | -0.1184 |
| 3799 | KIF5B | A002-C-201 | Human | Colorectum | FAP | 1.67e-09 | -9.01e-02 | 0.0324 |
| 3799 | KIF5B | A002-C-203 | Human | Colorectum | FAP | 1.21e-05 | 9.56e-02 | 0.2786 |
| 3799 | KIF5B | A001-C-119 | Human | Colorectum | FAP | 8.26e-05 | -1.22e-01 | -0.1557 |
| 3799 | KIF5B | A001-C-108 | Human | Colorectum | FAP | 7.72e-23 | 1.93e-01 | -0.0272 |
| 3799 | KIF5B | A002-C-205 | Human | Colorectum | FAP | 9.29e-23 | 8.41e-03 | -0.1236 |
| 3799 | KIF5B | A001-C-104 | Human | Colorectum | FAP | 5.82e-06 | 1.96e-01 | 0.0184 |
| 3799 | KIF5B | A015-C-005 | Human | Colorectum | FAP | 2.01e-02 | -7.44e-02 | -0.0336 |
| 3799 | KIF5B | A015-C-006 | Human | Colorectum | FAP | 4.40e-14 | -4.55e-03 | -0.0994 |
| 3799 | KIF5B | A015-C-106 | Human | Colorectum | FAP | 7.80e-10 | -2.46e-02 | -0.0511 |
| 3799 | KIF5B | A002-C-114 | Human | Colorectum | FAP | 2.98e-18 | -1.29e-01 | -0.1561 |
| 3799 | KIF5B | A015-C-104 | Human | Colorectum | FAP | 4.89e-28 | -1.23e-01 | -0.1899 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003070523 | Oral cavity | EOLP | cytoskeleton-dependent intracellular transport | 42/2218 | 195/18723 | 8.11e-05 | 9.69e-04 | 42 |
| GO:007134621 | Oral cavity | EOLP | cellular response to interferon-gamma | 29/2218 | 118/18723 | 9.03e-05 | 1.05e-03 | 29 |
| GO:005165022 | Oral cavity | EOLP | establishment of vesicle localization | 35/2218 | 161/18723 | 2.54e-04 | 2.47e-03 | 35 |
| GO:00309005 | Oral cavity | EOLP | forebrain development | 68/2218 | 379/18723 | 2.97e-04 | 2.79e-03 | 68 |
| GO:0009743110 | Oral cavity | EOLP | response to carbohydrate | 49/2218 | 253/18723 | 3.41e-04 | 3.15e-03 | 49 |
| GO:000808821 | Oral cavity | EOLP | axo-dendritic transport | 20/2218 | 75/18723 | 3.41e-04 | 3.15e-03 | 20 |
| GO:005164822 | Oral cavity | EOLP | vesicle localization | 37/2218 | 177/18723 | 3.88e-04 | 3.48e-03 | 37 |
| GO:000167817 | Oral cavity | EOLP | cellular glucose homeostasis | 36/2218 | 172/18723 | 4.51e-04 | 3.98e-03 | 36 |
| GO:0034284110 | Oral cavity | EOLP | response to monosaccharide | 44/2218 | 225/18723 | 5.38e-04 | 4.63e-03 | 44 |
| GO:0009746110 | Oral cavity | EOLP | response to hexose | 43/2218 | 219/18723 | 5.67e-04 | 4.81e-03 | 43 |
| GO:003577412 | Oral cavity | EOLP | positive regulation of insulin secretion involved in cellular response to glucose stimulus | 12/2218 | 36/18723 | 6.02e-04 | 5.04e-03 | 12 |
| GO:190300822 | Oral cavity | EOLP | organelle disassembly | 26/2218 | 114/18723 | 7.06e-04 | 5.78e-03 | 26 |
| GO:009893011 | Oral cavity | EOLP | axonal transport | 17/2218 | 64/18723 | 9.71e-04 | 7.35e-03 | 17 |
| GO:001097021 | Oral cavity | EOLP | transport along microtubule | 32/2218 | 155/18723 | 1.15e-03 | 8.37e-03 | 32 |
| GO:190547523 | Oral cavity | EOLP | regulation of protein localization to membrane | 35/2218 | 175/18723 | 1.26e-03 | 9.04e-03 | 35 |
| GO:190437523 | Oral cavity | EOLP | regulation of protein localization to cell periphery | 27/2218 | 125/18723 | 1.35e-03 | 9.36e-03 | 27 |
| GO:007133317 | Oral cavity | EOLP | cellular response to glucose stimulus | 31/2218 | 151/18723 | 1.50e-03 | 1.01e-02 | 31 |
| GO:00320247 | Oral cavity | EOLP | positive regulation of insulin secretion | 19/2218 | 78/18723 | 1.56e-03 | 1.05e-02 | 19 |
| GO:00024433 | Oral cavity | EOLP | leukocyte mediated immunity | 73/2218 | 440/18723 | 1.78e-03 | 1.16e-02 | 73 |
| GO:007133117 | Oral cavity | EOLP | cellular response to hexose stimulus | 31/2218 | 153/18723 | 1.87e-03 | 1.21e-02 | 31 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05012 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
| hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa05016 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
| hsa05014 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
| hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
| hsa04728 | Colorectum | AD | Dopaminergic synapse | 46/2092 | 132/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 46 |
| hsa050121 | Colorectum | AD | Parkinson disease | 147/2092 | 266/8465 | 2.53e-27 | 8.48e-25 | 5.41e-25 | 147 |
| hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa050161 | Colorectum | AD | Huntington disease | 147/2092 | 306/8465 | 1.93e-19 | 9.26e-18 | 5.91e-18 | 147 |
| hsa050201 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
| hsa050141 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
| hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
| hsa047281 | Colorectum | AD | Dopaminergic synapse | 46/2092 | 132/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 46 |
| hsa050124 | Colorectum | MSS | Parkinson disease | 140/1875 | 266/8465 | 2.32e-28 | 7.79e-26 | 4.77e-26 | 140 |
| hsa050104 | Colorectum | MSS | Alzheimer disease | 169/1875 | 384/8465 | 1.21e-22 | 1.01e-20 | 6.21e-21 | 169 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIF5B | SNV | Missense_Mutation | novel | c.1720G>T | p.Val574Leu | p.V574L | P33176 | protein_coding | tolerated(0.53) | benign(0) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| KIF5B | SNV | Missense_Mutation | novel | c.156N>A | p.Phe52Leu | p.F52L | P33176 | protein_coding | tolerated(0.31) | benign(0.17) | TCGA-AC-A2BK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| KIF5B | SNV | Missense_Mutation | c.591G>A | p.Met197Ile | p.M197I | P33176 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |
| KIF5B | SNV | Missense_Mutation | c.16N>A | p.Glu6Lys | p.E6K | P33176 | protein_coding | deleterious(0) | possibly_damaging(0.776) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| KIF5B | SNV | Missense_Mutation | novel | c.917C>T | p.Ser306Leu | p.S306L | P33176 | protein_coding | deleterious(0.01) | possibly_damaging(0.541) | TCGA-D8-A73X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| KIF5B | SNV | Missense_Mutation | rs746242956 | c.1415N>T | p.Ala472Val | p.A472V | P33176 | protein_coding | tolerated(0.23) | benign(0.104) | TCGA-EW-A6SB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KIF5B | insertion | Nonsense_Mutation | novel | c.1179_1180insTTAGCTTAAAAAGAGGGGGAAGA | p.Lys394LeufsTer3 | p.K394Lfs*3 | P33176 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| KIF5B | SNV | Missense_Mutation | novel | c.2104G>A | p.Glu702Lys | p.E702K | P33176 | protein_coding | deleterious(0.04) | possibly_damaging(0.589) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| KIF5B | SNV | Missense_Mutation | novel | c.2870N>C | p.Gly957Ala | p.G957A | P33176 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.981) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KIF5B | SNV | Missense_Mutation | novel | c.1892N>A | p.Ala631Glu | p.A631E | P33176 | protein_coding | tolerated(0.9) | benign(0.003) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |